Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denagliptin Monotherapy in Type 2 Diabetes
NCT00111800Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of denagliptin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by GSK. Primary endpoint: Glycosylated Hemoglobin at 12 weeks. Started Apr 2005; status: completed.
02
Drugs
denagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00111800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111800.